Cargando…

2566. infection Dynamics of Pseudomonas aeruginosa Bloodstream Infections

BACKGROUND: Pseudomonas aeruginosa (PA) is a critically important healthcare-associated pathogen responsible for a variety of infections including bloodstream infection (bacteremia), pneumonia, and urinary tract infection. PA bacteremia is a significant cause of morbidity and mortality, especially i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bachta, Kelly E R, Allen, Jonathan P, Hauser, Alan R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810250/ http://dx.doi.org/10.1093/ofid/ofz360.2244

Ejemplares similares

44. In-host Infection Dynamics Of Pseudomonas Aeruginosa Pneumonia
por: Bachta, Kelly E R, et al.
Publicado: (2020)

Systemic infection facilitates transmission of Pseudomonas aeruginosa in mice
por: Bachta, Kelly E. R., et al.
Publicado: (2020)

2682. Prophylaxis-Driven Molecular Epidemiology of Pseudomonas aeruginosa Bloodstream Infections in Adults With Leukemia
por: Endres, Bradley T, et al.
Publicado: (2019)

Vaccination to Prevent Pseudomonas aeruginosa Bloodstream Infections
por: Hart, Robert J., et al.
Publicado: (2022)

1589. Ceftolozane–Tazobactam Activity Against Difficult-to-Treat Resistance in Pseudomonas aeruginosa from Bloodstream Infections in US Hospitals
por: Shortridge, Dee, et al.
Publicado: (2019)

2453. Prolonged Local Epidemic of an XDR P. aeruginosa Subclade of High-Risk Clonal Complex 298
por: Pincus, Nathan B, et al.
Publicado: (2019)

Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections
por: Tschudin-Sutter, Sarah, et al.
Publicado: (2018)

Genomics of Aminoglycoside Resistance in Pseudomonas aeruginosa Bloodstream Infections at a United States Academic Hospital
por: Atassi, Giancarlo, et al.
Publicado: (2023)

736. Impact of COVID-19 on Mortality Associated with Pseudomonas aeruginosa Bloodstream Infection in the Veterans Health Administration System
por: Hojat, Leila S, et al.
Publicado: (2022)

61. Short- versus prolonged-courses of antimicrobial therapy for patients with uncomplicated Pseudomonas aeruginosa bloodstream infection
por: Bae, Moonsuk, et al.
Publicado: (2021)

1237. Characterization and crystallization of OXA-935, a novel class D OXA-10-like beta-lactamase, found in Pseudomonas aeruginosa
por: Pincus, Nathan B, et al.
Publicado: (2021)

Management of Pseudomonas aeruginosa Bloodstream Infection and Impact on Health Outcomes
por: Ramanathan, Swetha, et al.
Publicado: (2021)

Pseudomonas aeruginosa bloodstream infection at a tertiary referral hospital for children
por: Dame, Joycelyn Assimeng, et al.
Publicado: (2020)

2435. Clinical Outcomes With Ceftolozane–Tazobactam in Patients With Multidrug-Resistant (MDR) Pseudomonas aeruginosa Bloodstream Infections: A Multi-Center Study
por: King, Madeline, et al.
Publicado: (2018)

2566. Effect of CYP2C19 on Voriconazole Pharmacokinetics in Children with Malignancy or Inborn Errors in Immunity
por: Shoji, Kensuke, et al.
Publicado: (2023)

1114. Effectiveness and Safety of Beta-lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2021)

Risk Factors for Pseudomonas aeruginosa in Diabetic Foot Infections
por: Farhat, Nada, et al.
Publicado: (2017)

Multidrug-Resistant Pseudomonas Aeruginosa Bloodstream Infections: Analysis of Trends in Prevalence and Epidemiology
por: Tacconelli, Evelina, et al.
Publicado: (2002)

Risk Factors and Outcomes of Patients with Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infection
por: Wei, Xianzhen, et al.
Publicado: (2023)

584. Ventricular assist device infections with Pseudomonas aeruginosa
por: Roberts, Scott C, et al.
Publicado: (2020)

Comparison of severity of illness scoring systems for patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa
por: Marra, Alexandre R, et al.
Publicado: (2006)

Draft Genome Sequence of Pseudomonas aeruginosa Strain BWH047, a Sequence Type 235 Multidrug-Resistant Clinical Isolate Expressing High Levels of Colistin Resistance
por: Bachta, Kelly E. R., et al.
Publicado: (2019)

Comparison of the systemic inflammatory response syndrome between monomicrobial and polymicrobial Pseudomonas aeruginosa nosocomial bloodstream infections
por: Marra, Alexandre R, et al.
Publicado: (2005)

2254. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

Pseudomonas aeruginosa Bloodstream Infections in SARS-CoV-2 Infected Patients: A Systematic Review
por: Bongiovanni, Marco, et al.
Publicado: (2023)

Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models
por: Le, Hoan N., et al.
Publicado: (2019)

ZTI-01 Treatment Improves Survival of Animals Infected with Multidrug Resistant Pseudomonas aeruginosa
por: Lawrenz, Matthew B, et al.
Publicado: (2017)

Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins
por: Zaidenstein, Ronit, et al.
Publicado: (2018)

1274. Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam, and Comparators Against Pseudomonas aeruginosa Isolates from Patients with Bloodstream and Other Infection Types—SMART United States/Canada 2018-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

Characterization of the core and accessory genomes of Pseudomonas aeruginosa using bioinformatic tools Spine and AGEnt
por: Ozer, Egon A, et al.
Publicado: (2014)

Evaluation of Ceftazidime/Avibactam Administration in Enterobacteriaceae and Pseudomonas aeruginosa Bloodstream Infections by Monte Carlo Simulation
por: Dai, Yuanyuan, et al.
Publicado: (2021)

Decoding Genetic Features and Antimicrobial Susceptibility of Pseudomonas aeruginosa Strains Isolated from Bloodstream Infections
por: Bogiel, Tomasz, et al.
Publicado: (2022)

Clinical Characteristics and Prognosis of Bloodstream Infection with Carbapenem-Resistant Pseudomonas aeruginosa in Patients with Hematologic Malignancies
por: Yuan, Fangfang, et al.
Publicado: (2023)

Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors
por: Royo-Cebrecos, Cristina, et al.
Publicado: (2022)

413. Differences in Inflammatory Mechanisms in Pseudomonas aeruginosa and Staphyloccoccus auereus Infections in Cystic Fibrosis
por: Phuong, Melissa S, et al.
Publicado: (2019)

Ceftolozane-tazobactam for the Treatment of Multi Drug-resistant Pseudomonas aeruginosa (MDRPA) Infections
por: Molnar, Esther, et al.
Publicado: (2017)

2142. The use of Pseudomonas aeruginosa Phage PASA16 for non resolving infections
por: Onallah, Hadil, et al.
Publicado: (2023)

693. In Vitro Activity of Ceftazidime–Avibactam and Comparator Agents Against Enterobacteriaceae and Pseudomonas aeruginosa Collected From Patients with Bloodstream Infections as Part of the ATLAS Global Surveillance Program, 2014–2017
por: Kazmierczak, Krystyna, et al.
Publicado: (2019)

1047. Global Surveillance: Susceptibility of Ceftolozane–Tazobactam Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa Isolates Collected From Bloodstream Infections in the United States From 2015 to 2017
por: Arends, S J Ryan, et al.
Publicado: (2018)

1719. In Vitro Activity of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected from Patients with Bloodstream Infections as Part of the ATLAS Global Surveillance Program, 2017-2020
por: Estabrook, Mark, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_11mpfgrg2hh2j77bukmnv9b1p3